A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Latest Information Update: 24 Sep 2021
At a glance
- Drugs Tesevatinib (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Kadmon Corporation
- 17 Jun 2020 Status changed from active, no longer recruiting to completed.
- 18 Feb 2020 Planned End Date changed from 1 Feb 2020 to 31 Mar 2020.
- 18 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 31 Mar 2020.